---
document_datetime: 2025-12-29 13:58:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-jensonr.html
document_name: ivabradine-jensonr.html
version: success
processing_time: 0.1017905
conversion_datetime: 2025-12-30 03:20:22.346694
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ivabradine JensonR

[RSS](/en/individual-human-medicine.xml/66610)

##### Withdrawn

This medicine's authorisation has been withdrawn

ivabradine Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ivabradine JensonR](#news-on)
- [Related information](#related-information-737)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 6 December 2018, the European Commission withdrew the marketing authorisation for Ivabradine JensonR (ivabradine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, JensonR+ Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Ivabradine JensonR was granted marketing authorisation in the EU on 11 November 2016 for the treatment of angina pectoris and chronic heart failure. The marketing authorisation was initially valid for 5 years. The product had not been marketed in the EU since the marketing authorisation was granted.

Ivabradine JensonR is a generic medicine of ivabradine. Other generic medicinal products of ivabradine are authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Ivabradine JensonR is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Ivabradine JensonR : EPAR - Summary for the public

Reference Number: EMA/624480/2016

English (EN) (562.96 KB - PDF)

**First published:** 08/02/2017

**Last updated:** 20/12/2018

[View](/en/documents/overview/ivabradine-jensonr-epar-summary-public_en.pdf)

[Other languages (20)](#file-language-dropdown-419)

български (BG) (641.45 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/bg/documents/overview/ivabradine-jensonr-epar-summary-public_bg.pdf)

español (ES) (563.56 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/es/documents/overview/ivabradine-jensonr-epar-summary-public_es.pdf)

čeština (CS) (608.35 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/cs/documents/overview/ivabradine-jensonr-epar-summary-public_cs.pdf)

dansk (DA) (556.75 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/da/documents/overview/ivabradine-jensonr-epar-summary-public_da.pdf)

Deutsch (DE) (560.52 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/de/documents/overview/ivabradine-jensonr-epar-summary-public_de.pdf)

eesti keel (ET) (557.19 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/et/documents/overview/ivabradine-jensonr-epar-summary-public_et.pdf)

ελληνικά (EL) (648.85 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/el/documents/overview/ivabradine-jensonr-epar-summary-public_el.pdf)

français (FR) (560.43 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/fr/documents/overview/ivabradine-jensonr-epar-summary-public_fr.pdf)

hrvatski (HR) (580.51 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/hr/documents/overview/ivabradine-jensonr-epar-summary-public_hr.pdf)

italiano (IT) (546.11 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/it/documents/overview/ivabradine-jensonr-epar-summary-public_it.pdf)

latviešu valoda (LV) (622.17 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/lv/documents/overview/ivabradine-jensonr-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (584.63 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/lt/documents/overview/ivabradine-jensonr-epar-summary-public_lt.pdf)

magyar (HU) (617.34 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/hu/documents/overview/ivabradine-jensonr-epar-summary-public_hu.pdf)

Nederlands (NL) (559.95 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/nl/documents/overview/ivabradine-jensonr-epar-summary-public_nl.pdf)

polski (PL) (623.46 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/pl/documents/overview/ivabradine-jensonr-epar-summary-public_pl.pdf)

română (RO) (583.35 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/ro/documents/overview/ivabradine-jensonr-epar-summary-public_ro.pdf)

slovenčina (SK) (623.21 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sk/documents/overview/ivabradine-jensonr-epar-summary-public_sk.pdf)

slovenščina (SL) (615.3 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sl/documents/overview/ivabradine-jensonr-epar-summary-public_sl.pdf)

Suomi (FI) (559.23 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/fi/documents/overview/ivabradine-jensonr-epar-summary-public_fi.pdf)

svenska (SV) (541.56 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sv/documents/overview/ivabradine-jensonr-epar-summary-public_sv.pdf)

## Product information

Ivabradine JensonR : EPAR - Product Information

English (EN) (876.88 KB - PDF)

**First published:** 08/02/2017

**Last updated:** 20/12/2018

[View](/en/documents/product-information/ivabradine-jensonr-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-8)

български (BG) (1.99 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/bg/documents/product-information/ivabradine-jensonr-epar-product-information_bg.pdf)

español (ES) (950.6 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/es/documents/product-information/ivabradine-jensonr-epar-product-information_es.pdf)

čeština (CS) (1.55 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/cs/documents/product-information/ivabradine-jensonr-epar-product-information_cs.pdf)

dansk (DA) (895.97 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/da/documents/product-information/ivabradine-jensonr-epar-product-information_da.pdf)

Deutsch (DE) (897.68 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/de/documents/product-information/ivabradine-jensonr-epar-product-information_de.pdf)

eesti keel (ET) (872.13 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/et/documents/product-information/ivabradine-jensonr-epar-product-information_et.pdf)

ελληνικά (EL) (2.04 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/el/documents/product-information/ivabradine-jensonr-epar-product-information_el.pdf)

français (FR) (900.33 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/fr/documents/product-information/ivabradine-jensonr-epar-product-information_fr.pdf)

hrvatski (HR) (959.84 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/hr/documents/product-information/ivabradine-jensonr-epar-product-information_hr.pdf)

íslenska (IS) (910.23 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/is/documents/product-information/ivabradine-jensonr-epar-product-information_is.pdf)

italiano (IT) (883.37 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/it/documents/product-information/ivabradine-jensonr-epar-product-information_it.pdf)

latviešu valoda (LV) (1.58 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/lv/documents/product-information/ivabradine-jensonr-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1005.27 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/lt/documents/product-information/ivabradine-jensonr-epar-product-information_lt.pdf)

magyar (HU) (1.49 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/hu/documents/product-information/ivabradine-jensonr-epar-product-information_hu.pdf)

Malti (MT) (1.54 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/mt/documents/product-information/ivabradine-jensonr-epar-product-information_mt.pdf)

Nederlands (NL) (896.77 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/nl/documents/product-information/ivabradine-jensonr-epar-product-information_nl.pdf)

norsk (NO) (864.21 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/no/documents/product-information/ivabradine-jensonr-epar-product-information_no.pdf)

polski (PL) (1.59 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/pl/documents/product-information/ivabradine-jensonr-epar-product-information_pl.pdf)

português (PT) (887.08 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/pt/documents/product-information/ivabradine-jensonr-epar-product-information_pt.pdf)

română (RO) (1003.16 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/ro/documents/product-information/ivabradine-jensonr-epar-product-information_ro.pdf)

slovenčina (SK) (1.52 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sk/documents/product-information/ivabradine-jensonr-epar-product-information_sk.pdf)

slovenščina (SL) (1.51 MB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sl/documents/product-information/ivabradine-jensonr-epar-product-information_sl.pdf)

Suomi (FI) (966.38 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/fi/documents/product-information/ivabradine-jensonr-epar-product-information_fi.pdf)

svenska (SV) (878.51 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sv/documents/product-information/ivabradine-jensonr-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** - 11/11/2016

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ivabradine JensonR : EPAR - All Authorised presentations

English (EN) (477.61 KB - PDF)

**First published:** 08/02/2017

**Last updated:** 20/12/2018

[View](/en/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-908)

български (BG) (554.28 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/bg/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_bg.pdf)

español (ES) (481.73 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/es/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_es.pdf)

čeština (CS) (533.46 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/cs/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (480.27 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/da/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_da.pdf)

eesti keel (ET) (480.28 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/et/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_et.pdf)

français (FR) (479.6 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/fr/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (512.01 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/hr/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (478.25 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/is/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_is.pdf)

italiano (IT) (479.83 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/it/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (540.45 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/lv/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (514.1 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/lt/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (537.43 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/hu/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (535.27 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/mt/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (481.16 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/nl/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (480.04 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/no/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_no.pdf)

português (PT) (480.69 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/pt/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_pt.pdf)

română (RO) (511.92 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/ro/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (540.17 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sk/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (524.37 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sl/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (480.54 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/fi/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (480.94 KB - PDF)

**First published:**

08/02/2017

**Last updated:**

20/12/2018

[View](/sv/documents/all-authorised-presentations/ivabradine-jensonr-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ivabradine JensonR Active substance ivabradine hydrochloride International non-proprietary name (INN) or common name ivabradine Therapeutic area (MeSH)

- Angina Pectoris
- Heart Failure

Anatomical therapeutic chemical (ATC) code C01EB17

### Pharmacotherapeutic group

Cardiac therapy

### Therapeutic indication

Symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm. Ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

## Authorisation details

EMA product number EMEA/H/C/004217

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

JensonR+ Limited

Fishleigh Court

Opinion adopted 15/06/2016 Marketing authorisation issued 11/11/2016 Withdrawal of marketing authorisation 06/12/2018

## Assessment history

## Initial marketing authorisation documents

Ivabradine JensonR : EPAR - Public assessment report

Adopted

Reference Number: EMA/648588/2016

English (EN) (1.25 MB - PDF)

**First published:** 08/02/2017

**Last updated:** 20/12/2018

[View](/en/documents/assessment-report/ivabradine-jensonr-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ivabradine JensonR

Adopted

Reference Number: EMA/CHMP/605096/2016

English (EN) (545.32 KB - PDF)

**First published:** 16/09/2016

**Last updated:** 20/12/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ivabradine-jensonr_en.pdf)

#### News on Ivabradine JensonR

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected)](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2016-corrected) 21/09/2016

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC0042170000) (initial marketing authorisation)

**This page was last updated on** 20/12/2018

## Share this page

[Back to top](#main-content)